Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

SureCN1272489 (4S,5R,6R)-5-acetamido-4...

Synonyms: AC1LCS75, D01937, Zanamivir hydrate (JAN)

This record was replaced with 60855.

Morris, S.J. et al., Oxford, J.S., Fenton, R.J. et al., Schmidt, R.E., Barnett, D.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Zanamavir

Zanamivir (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid; Relenza; GG167) is a potent and highly specific neuraminidase (sialidase) inhibitor with inhibitory activity in vivo against both influenza A and B viruses [1].
Previously, we have shown that apoptosis induced by influenza virus was inhibited by an anti-neuraminidase compound [4-guanidino-2, 3-dehydro-N-acetylneuraminic acid (GG167; Relenza; Zanamivir)], which does not enter cells, and acts at the attachment/entry phase of virus replication [2].

High impact information on Zanamavir

Clinical effectiveness and cost effectiveness of zanamivir (Relenza): translating the evidence into clinical practice, a National Institute for Clinical Excellence view [3].
With zanamivir (Relenza), a selective inhibitor of the influenza-specific neuraminidase, a pharmaceutical product against influenza A and B is now available in Germany for the very first time [4].
In October 1999, the British Pharma Group (BPG) wrote to the UK Prime Minister to seek a discussion on the implications for the British-based pharmaceutical industry of the recommendation from NICE's Raised Appraisal Committee that Relenza should be banned from the NHS [342597] [5].

References

Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract. Fenton, R.J., Morley, P.J., Owens, I.J., Gower, D., Parry, S., Crossman, L., Wong, T. Antimicrob. Agents Chemother. (1999) [Pubmed]
Exploitation of the Herpes simplex virus translocating protein VP22 to carry influenza virus proteins into cells for studies of apoptosis: direct confirmation that neuraminidase induces apoptosis and indications that other proteins may have a role. Morris, S.J., Smith, H., Sweet, C. Arch. Virol. (2002) [Pubmed]
Clinical effectiveness and cost effectiveness of zanamivir (Relenza): translating the evidence into clinical practice, a National Institute for Clinical Excellence view. Barnett, D. Philos. Trans. R. Soc. Lond., B, Biol. Sci. (2001) [Pubmed]
Drug under test: influenza--Relenza in daily practice. Experience during the influenza season 1999/2000. Schmidt, R.E. Med. Microbiol. Immunol. (Berl.) (2002) [Pubmed]
Zanamivir (Glaxo Wellcome). Oxford, J.S. IDrugs : the investigational drugs journal. (2000) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

Editor

Share